News – Droia Ventures – Investing in Impact

Frontier Medicines Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipeline

Funding to Enhance Research and Development of Pipeline, Including Lead Program Targeting Activated KRAS^G12C. Proceeds to Further Accelerate the Development of Foundational Technologies in Chemoproteomics, Covalent Drug Discovery and Machine Learning. Distinguished Scientific Advisory Board Announced. Expansion of Frontier Operations with Opening of Boston Facility...

19 July, 2021

Muna Therapeutics Launches with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases

announced the successful closing of a US$ 73 million (EUR 60 million) Series A financing round. The investor syndicate was co-led by Novo Holdings, Sofinnova Partners, Droia Ventures and LSP Dementia Fund, with Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures and VIB joining...

09 July, 2021

Belgisch alzheimeronderzoek trekt 60 miljoen euro aan

De start-ups K5 Therapeutics (België) en Muna Therapeutics (Denemarken) bundelen de krachten. De fusiegroep haalt 60 miljoen euro op voor alzheimeronderzoek. Het Belgische investeringsfonds Droia stond mee aan de wieg van K5 en legt deze keer 12 miljoen euro op tafel. K5 groeide uit het...

09 July, 2021

Cyteir Therapeutics Announces Pricing of Initial Public Offering

The gross proceeds of the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Cyteir, are expected to be approximately $133 million excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on...

17 June, 2021

Montis Biosciences Awarded VLAIO Grant to Expand its Pipeline of Novel Immune-Oncology Therapeutics

Montis announces the award of a EUR 1 million research grant by Flanders Innovation & Entrepreneurship (VLAIO). The grant will be used to accelerate validation and development of Montis Biosciences’ pipeline of novel cancer therapeutics for the treatment of solid tumors....

14 June, 2021

Hummingbird Bioscience Raises US$125 Million in Series C Financing

“We are delighted to have the support and confidence of leading global healthcare investors to advance the development of our unique pipeline of precision therapies against important, yet hard-to-drug targets. We have made tremendous progress since closing our Series B in 2019 and this financing...

18 May, 2021

Droia Ventures raises a new fund of EUR 220 million to target genetic diseases and expands leadership team with George Golumbeski

George Golumbeski has joined the Droia partnership to reinforce the team with the launch of the new fund. Golumbeski is the former Executive Vice President of Business Development at Celgene, where he was a major architect of Celgene’s successful biotech collaboration and acquisition strategy. Post...

11 May, 2021

Volastra Therapeutics extends seed financing to $44 million to advance drug discovery programs to prevent cancer metastasis

“The support of our new and existing investors reflects the increasing interest around CIN as a core driver in cancer biology,” said Charles Hugh-Jones, M.D., Volastra’s Chief Executive Officer. “This latest financing places us in a position of strength to advance our bold vision to...

06 April, 2021

Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance Clinical Trials of Lead RAD51 Program

“We are intrigued by the potential of RAD-51 inhibition, particularly due to early findings suggesting it could be helpful in treating lymphomas and other hematologic malignancies,” said Derek DiRocco, Ph.D., partner, RA Capital Management. “This promising mechanism, coupled with the demonstrated efficiency and expertise of...

11 February, 2021

Aura Biosciences Appoints David Johnson to Its Board of Directors

With David’s impressive track record in oncology and as an accomplished CEO, his engagement and guidance will help Aura drive AU-011 for the treatment of choroidal melanoma to registration and commercialization,” said George Golumbeski, Ph.D., Chairman of the Board of Aura Biosciences....

05 January, 2021